128
Participants
Start Date
March 31, 2009
Primary Completion Date
December 31, 2009
Study Completion Date
February 28, 2010
AEG33773 oral dosing
AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
University Multiprofile Hospital for Active Treatment - Clinic of Endocrinology and Metabolic Diseases, Plovdiv
University Multiprofile Hospital for Active Treatment - Clinic of Endocrinology and Metabolic Diseases, Pleven
University Multiprofile Hospital Treatment Stara Zagora, Stara Zagora
Multiprofile Hospital for Active Treatment - Therapeutical and Endocrinology Department, Rousse
Multiprofile Hospital for Active Treatment - Internal Department, Byala
Altoona Center for Clinical Research, Duncansville
Radiant Research, Cincinnatti
Wells Institute for Health Awareness, Kettering
UT Southwestern Medical Center, Dallas
Neurological Research Institute, Santa Monica
"Medical Center Dr. Negrisanu SRL", Timișoara
St. Spiridon Emergency Clinical County Hospital, Iași
Emergency Clinical County Hospital Cluj County, Cluj-Napoca
Clinique d'Endocrinologie de l'Outaouais, Hull
Centre de Recherche Clinique de Laval, Laval
Hopital de l'Enfant Jesus, Québec
S.C. Nicodiab SRL, Bucharest
National Clinical Institute of Diabetes, Nutrition and Metabolic Diseases, Bucharest
National Institute of Diabetes Nutrition and Metabolic Diseases, Bucharest
Mosilor Diabetes Mellitus and Obesity Medical, Bucharest
Lead Sponsor
Aegera Therapeutics
INDUSTRY